Login
Subscribe
Take a FREE Trial
About Us
Contact us
RSS
18 May 2013
Search
The Pharma Letter
Home
7 Day Premium Trial
Pharmaceuticals
Biotechnology
Generics
Events
Companies
Drugs
Subscribe
Andromeda Articles
Andromeda’s type 1 diabetes candidate DiaPep277 meets Ph III primary endpoint
22 November 2011
Teva invests further in diabetes treatment firm Andromeda
15 June 2010
Showing 1-2 of 2 articles
1
Hot Topics
Most Read
Encouraging results with Sangamo's SB-728-T in HIV treatment
Bristol-Myers' data on Yervoy and nivolumab causes a stir
Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
Neovacs moving forward in rheumatoid arthritis, say analysts
Encouraging results with Sangamo's SB-728-T in HIV treatment
Bristol-Myers' data on Yervoy and nivolumab causes a stir
Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
Neovacs moving forward in rheumatoid arthritis, say analysts